GlassScriptPhysician profile
Wisna Jean
NPI 1780947424
$4,683.07
in general payments reported to CMS, 2019-2025
19 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.99 · 2022: $340 · 2023: $1,403 · 2024: $1,650 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,104 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.53 |
| Education | $169.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $972.92 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $910.23 | 2022-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $419.18 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $352.12 | 2021-2025 | Arikayce |
| Abbvie INC. | $340.40 | 2023-2025 | |
| Shionogi INC | $331.28 | 2023-2025 | Fetroja |
| Melinta Therapeutics, LLC | $226.67 | 2022-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Astellas Pharma US INC | $192.95 | 2022-2023 | Cresemba |
| Theratechnologies INC. | $190.90 | 2023-2025 | Egrifta, Trogarzo, Egrifta Sv |
| La Jolla Pharmaceutical Company | $151.59 | 2023-2025 | Xerava, Zevtera |
| Paratek Pharmaceuticals, INC. | $132.07 | 2023-2025 | Nuzyra |
| Janssen Biotech, INC. | $112.32 | 2022-2023 | Symtuza |
| Pfizer INC. | $83.92 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.85 | 2024 | Hyqvia |
| Aimmune Therapeutics, INC. | $68.47 | 2023-2025 | Vowst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $54.60 | 2023 | Hizentra |
| Tetraphase Pharmaceuticals, INC. | $24.84 | 2025 | |
| Glaxosmithkline, LLC. | $18.95 | 2024 | Menveo, Flulaval Quadrivalent |
| Grifols USA, LLC | $17.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wisna Jean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.